The Future of Pharmaceutical Manufacturing: Flexibility and Sustainability through Small-Footprint, Modular Equipment Trains
Posted on November 13, 2025
Daniel O. Blackwood, Research Fellow
Jeffrey Moriarty, Director, (Previously Principal Scientist)
Pfizer
Introduction Following a decade (or more)1 of concerted effort by industry, regulator, and academic groups, recent technology investments are now beginning to shape how medicines are being developed and manufactured for the global marketplace. While significant focus has highlighted the emergence of...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
an immediate-release solid oral dosage, commercial supply flexibility, continuous manufacturing processes, Daniel O. Blackwood, distribution, extended supply chain networks, FDA’s Breakthrough Therapy designation, Flexability, high-value personalized medicines, Jeffrey Moriarty, manufacturing, manufacturing localization, Modular Equipment Trains, new regulatory pathways, Pfizer, pharmaceutical development, product development speed, Small Footprint, supply chain networks, sustaianability, targeted biology
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
